The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Dapagliflozin (Primary) ; Sitagliptin
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DIVERSITY-CVR study
- 02 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2017 Status changed from not yet recruiting to recruiting.
- 03 Jul 2017 New trial record